Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17607072 | MESOIONIC IMIDAZOLIUM COMPOUNDS AND DERIVATIVES FOR COMBATING ANIMAL PESTS | Final Rejection | BASF SE |
| 18555095 | NOVEL USE | Non-Final OA | DSM IP Assets B.V. |
| 18502780 | NOVEL PRMT5 INHIBITORS | Non-Final OA | AMGEN INC. |
| 18497645 | BIO-ORTHOGONAL DRUG ACTIVATION | Non-Final OA | Tagworks Pharmaceuticals B.V. |
| 18547618 | A QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THE PREPARATION THEREOF | Non-Final OA | ZYDUS LIFESCIENCES LIMITED |
| 18570761 | METHOD FOR PRODUCING ISOXAZOLINECARBOXYLIC ACID DERIVATIVES | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 18276527 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Non-Final OA | ElevateBio TechnologieS, Inc. |
| 18646220 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | Non-Final OA | Denali Therapeutics Inc. |
| 18437558 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Final Rejection | Bial - R&D Investments, S.A. |
| 18294596 | SMALL MOLECULE INHIBITORS FOR ANTI-CANCER COMBINATION THERAPY | Non-Final OA | UNIVERSITY OF CAPE TOWN |
| 18290604 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | Non-Final OA | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED |
| 18581000 | NOVEL COMPOUNDS AND USES THEREOF | Non-Final OA | Royston Anthony GRAY |
| 18023164 | NOVEL COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | Non-Final OA | Vicore Pharma AB |
| 18574248 | CRYSTALLINE POLYMORPHS OF EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR, AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | Crimson BioPharm Inc. |
| 18381121 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Non-Final OA | ZHEJIANG GENFLEET THERAPEUTICS CO.,LTD. |
| 18533681 | HOST DIRECTED DRUG COMBINATIONS FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | SystaMedic Inc. |
| 18388554 | Pre And Post Natal Compositions Including Carotenoids | Non-Final OA | Maravilla, LLC |
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Non-Final OA | MONTELINO THERAPEUTICS, INC. |
| 18555250 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | Non-Final OA | ASIA VISION LIMITED |
| 18463587 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | Non-Final OA | FORMA Therapeutics, Inc. |
| 18356148 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Non-Final OA | FireFly Bio, Inc. |
| 17725689 | AMIDE-LINKED CONJUGATE COMPOUNDS AND USES THEREOF | Non-Final OA | SIMON FRASER UNIVERSITY |
| 18162976 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Non-Final OA | Beckley Psytech Limited |
| 18011590 | TYK-2 INHIBITOR | Non-Final OA | BEIGENE, LTD. |
| 17625698 | PHENYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Non-Final OA | Cura Therapeutics, LLC |
| 17594474 | Bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and use thereof | Final Rejection | HINOVA PHARMACEUTICALS INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy